Benzalkonium chloride, often shortened to BAK or BAC, can preserve eye drops and other medicines and also appears in antiseptics, disinfectants, and personal-care products. It is a recognized irritant and a possible contact allergen. That combination makes a weak patch-test reaction difficult to read: the test must be interpreted with its shape, strength, timing, and a real exposure that fits the rash.
Irritation and contact allergy are different findings
Irritant contact dermatitis comes from direct damage to the skin barrier and does not require prior immune sensitization. Allergic contact dermatitis is a delayed immune response in someone who has become sensitized. Burning, itching, redness, scaling, or eyelid swelling cannot reliably distinguish the two by themselves. The same person can also have another eyelid condition, an allergy to a different ingredient, or ocular-surface irritation rather than skin allergy.
A Melbourne tertiary clinic reviewed 7,390 patients patch tested with BAK from 2003 through 2019. Of those patients, 108 had a positive reaction, but only 21 positive reactions were judged clinically relevant; five additional doubtful reactions were considered relevant after exposure assessment. The total—26 patients, or 0.4% of everyone tested—shows why a test mark and clinical relevance are separate decisions. These are specialist-clinic data, not prevalence in the public. Read the study.
Eye drops require a complete medicine history
In that Melbourne study, ophthalmic drops were the most frequently recorded exposure among relevant reactions. A 2026 report also described three patients with allergic contact dermatitis from BAK in eye drops. A case series can show that this route occurs; it cannot tell how often it occurs or prove that BAK explains every rash in someone using drops.
For each eye medicine, record the exact product, active drug, preservative and other inactive ingredients, start date, dosing schedule, which eye receives it, and where liquid contacts the eyelids or cheeks. Add artificial tears, contact-lens solutions, ointments, lid cleansers, cosmetics, and applicators. If more than one bottle is used, keep each timeline separate.
Hypothetical worked example
A person uses a prescribed glaucoma drop at night and an over-the-counter lubricating drop during the day. Eyelid scaling began after the lubricant was added, but both labels list benzalkonium chloride and each formula has different active and inactive ingredients. The timeline makes BAK one hypothesis, not the diagnosis. The eye-care prescriber and patch-test clinician need both packages, the drop schedule, photos, and the exact skin distribution before deciding what is relevant.
Patch-test interpretation needs more than one reading
BAK's irritant potential means a doubtful or weak reaction deserves caution. The 2026 European patch-testing guideline recommends reading reactions over time and interpreting morphology, exposure, and relevance together. A clinician may consider the broader series, other product ingredients, personal products, and whether the reaction persists or changes at later readings. Do not conduct an open application test or place eye drops, disinfectant, or patch-test material on unaffected skin or the eyelid yourself.
Co-positivity with another preservative or quaternary ammonium compound does not by itself prove cross-reaction. Ask which exact substance was tested, whether the reading was positive, doubtful, or irritant, and what exposure made it relevant. A family name alone is not a safe basis for avoiding every chemically related ingredient.
Bring specific questions to both clinicians
- Does the rash involve eyelid skin, the ocular surface, or both, and what diagnoses are being considered?
- Which current medicines contain BAK, and which other active or inactive ingredients need review?
- Was the BAK patch-test reaction allergic, doubtful, or irritant, and what did later readings show?
- Does the timing and contact pattern support current relevance?
- If a medicine change is appropriate, how will the prescriber protect the condition being treated?
Do not stop or replace a prescribed eye medicine because of an ingredient match or patch-test result. Contact the eye-care prescriber and explain the skin or eye symptoms. Eye pain, vision change, marked swelling, light sensitivity, discharge, or rapidly worsening symptoms need prompt clinical assessment. For transferred and airborne routes beyond drops, use the eyelid exposure guide.
Sources
- Dear K, et al. Contact allergy and allergic contact dermatitis from benzalkonium chloride in a tertiary dermatology center in Melbourne, Australia. Contact Dermatitis. 2021;85(2):146–153. PMID: 33656745. DOI: 10.1111/cod.13826.
- Kannen A, Harrison P, Christou E. Benzalkonium Chloride in Eye Drops Causing Allergic Contact Dermatitis: A Case Series. Australasian Journal of Dermatology. Published online July 2, 2026. DOI: 10.1111/ajd.70163.
- Uter W, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing, update 2026. Contact Dermatitis. 2026. DOI: 10.1111/cod.70195.